From a therapeutic perspective, our findings highlight the possibility that anti‐amyloid therapies may be beneficial to slow cognitive dysfunction in the symptomatic phase of AD by reducing amyloid‐β potentiating of tau’s pathological effects. The gene discussed is MAPT; the disease is Alzheimer disease.